Media Releases › Arovella Therapeutics

SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the second quarter of FY2019.

For more information, download the attached PDF.

  Download this document